HOMA-AD in Assessing Insulin Resistance in Lean Noncirrhotic HCV Outpatients
| Autor: | Oscar Augusto Birkhan, Matheus Truccolo Michalczuk, Camila Rippol Kappel, Mário Reis Álvares-da-Silva, Ana Carolina Costa Bragança |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
medicine.medical_specialty
Pathology Hepatology Adiponectin Article Subject business.industry Insulin medicine.medical_treatment nutritional and metabolic diseases medicine.disease Gastroenterology Fasting glucose Insulin resistance Internal medicine Clinical Study Medicine lcsh:Diseases of the digestive system. Gastroenterology lcsh:RC799-869 business hormones hormone substitutes and hormone antagonists |
| Zdroj: | International Journal of Hepatology International Journal of Hepatology, Vol 2012 (2012) |
| ISSN: | 2090-3456 |
| Popis: | Introduction. There is an association between HCV and insulin resistance (IR), which is currently assessed by HOMA-IR. There is evidence that HOMA-adiponectin (HOMA-AD) is more accurate, but its role in HCV patients is unknown. The purpose of this study was to evaluate IR in an HCV sample and controls, in order to compare the accuracy of HOMA-IR and HOMA-AD.Methods. Ninety-four HCV outpatients aged Results. The groups were similar regarding sex and BMI, but the HCV patients were older. The median insulin level was higher in the HCV group (8.6 mU/mL (6.5–13.7) versus 6.5 (4.3–10.7),P=0.004), as was median HOMA-IR (1.94 (1.51 to 3.48) versus 1.40 (1.02 to 2.36),P=0.002) and the prevalence of IR (38.3% versus 10.3% (P=0.009)). No differences were found in adiponectin levels (P=0.294) and HOMA-AD (P=0.393).Conclusion. IR is highly prevalent even in low-risk HCV outpatients. Adiponectin is not influenced by the presence of HCV. HOMA-AD does not seem to be useful in assessing IR in HCV patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text